Abstract
Gene transfer vectors expressing herpes simplex thymidine kinase (HSVtk), in addition to direct killing of tumor cells, often have an associated local ‘bystander effect’ mediated by metabolic coupling of tumor cells. A systemic antitumor effect mediated by the immune system, termed the distant bystander effect, has also been reported. We have observed the development of cytotoxic T-lymphocyte (CTL) populations and long-lasting antitumor immunity following treatment of subcutaneous tumors with an adenoviral vector expressing HSVtk (AV.TK) and ganciclovir (GCV) in rat glioma model. This vaccination effect seen with AV.TK/GCV treatment of subcutaneous tumor could even abrogate or retard growth of previously established secondary intracranial tumors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kayama T, Kumabe T, Tominaga T, Yoshimoto T . Prognostic value of complete response after the initial treatment for malignant astrocytoma Neurol Res 1996 18: 321–324
Wen PY et al. High-grade astrocytomas Neurol Clin 1995 13: 875–900
Blaese RM et al. Brain tumor treatment: significant contributions Science 1992 18: 1960
Culver KW et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors Science 1992 256: 1550–1552
Ram Z et al. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats Cancer Res 1993 53: 83–88
Kun LE et al. Stereotactic injection of herpes simplex thymidine kinase vector producer cells (PA317-G1Tk1SvNa.7) and intravenous ganciclovir for the treatment of progressive or recurrent primary supratentorial pediatric malignant brain tumors Hum Gene Ther 1995 6: 1231–1255
Ram Z et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells Nat Med 1997 3: 1354–1361
Bi WL, Parysek LM, Warnick R, Stambrook PJ . In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSVtk retroviral gene therapy Hum Gene Ther 1993 4: 725–731
Touraine RL, Vahanian N, Ramsey WJ, Blaese RM . Enhancement of the herpes simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor efficacy in vivo by pharmacologic manipulation of gap junctions Hum Gene Ther 1998 9: 2385–2391
Vieweg J, Gilboa E . Considerations for the use of cytokine-secreting tumor cell preparations for cancer treatment Cancer Invest 1995 13: 193–201
Cavallo F et al. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12 J Natl Cancer Inst 1997 89: 1049–1058
Ashley DM et al. A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo J Neuroimmunol 1997 78: 34–46
Ashley DM et al. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors J Exp Med 1997 186: 1177–1182
Kurpad SN et al. Tumor antigens in astrocytic gliomas Glia 1995 15: 244–256
Yamamoto S et al. Herpes simplex virus thymidine kinase/ganciclovir-mediated killing of tumor cell induces tumor-specific cytotoxic T cells in mice Cancer Gene Ther 1997 4: 91–96
Melcher A et al. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression Nat Med 1998 4: 581–587
Yu JS, Burwick JA, Dranoff G, Breakefield XO . Gene therapy for metastatic brain tumors by vaccination with granulocyte–macrophage colony-stimulating factor-transduced tumor cells Hum Gene Ther 1997 8: 1065–1072
Nair SK, Boczkowski D, Snyder D, Gilboa E . Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines Eur J Immunol 1997 27: 589–597
Okada H et al. Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSVtk tumor vaccine Gene Therapy 1999 6: 219–226
Todo T et al. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus Hum Gene Ther 1999 10: 2741–2755
Ertl HC, Xiang Z . Novel vaccine approaches J Immunol 1996 156: 3579–3582
Vincent AJ et al. Preclinical testing of recombinant adenoviral herpes simplex virus-thymidine kinase gene therapy for central nervous system malignancies Neurosurgery 1997 41: 442–451
Brody SL, Crystal RG . Adenovirus-mediated in vivo gene transfer Ann NY Acad Sci 1994 31: 90–101
Caillaud C et al. Adenoviral vector as a gene delivery system into cultured rat neuronal and glial cells Eur J Neurosci 1993 5: 1287–1291
Takeuchi Y et al. Sensitization of cells and retroviruses to human serum by (alpha 1–3) galactosyltransferase Nature 1996 379: 85–88
Perez-Cruet MJ et al. Adenovirus-mediated gene therapy of experimental gliomas J Neurosci Res 1994 39: 506–511
Chen J et al. Effects of the MYC oncogene antagonist, MAD, on proliferation, cell cycling and the malignant phenotype of human brain tumour cells Nat Med 1995 1: 638–643
Vincent AJ et al. Herpes simplex virus thymidine kinase gene therapy for rat malignant brain tumors Hum Gene Ther 1996 7: 197–205
Smith JG et al. Intracranial administration of adenovirus expressing HSV-TK in combination with ganciclovir produces a dose-dependent, self-limiting inflammatory response Hum Gene Ther 1997 8: 943–954
Bacso Z et al. A photobleaching energy transfer analysis of CD8/MHC-I and LFA-1/ICAM-1 interactions in CTL-target cell conjugates Immunol Lett 1996 54: 151–156
Sun J, Kavathas PB . Comparison of the roles of CD8 alpha alpha and CD8 alpha beta in interaction with MHC class I J Immunol 1997 159: 6077–6082
Renard V et al. CD8 beta increases CD8 coreceptor function and participation in TCR-ligand binding J Exp Med 1996 184: 2439–2444
Ferrarini M, Heltai S, Chiesa G, Sabbadini MG . V delta 1+ gamma/delta T lymphocytes infiltrating human lung cancer express the CD8 alpha/alpha homodimer Scand J Immunol 1994 40: 363–367
Barba D et al. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors Proc Natl Acad Sci USA 1994 91: 4348–4352
Wen PY, Lampson MA, Lampson LA . Effects of gamma-interferon on major histocompatibility complex antigen expression and lymphocytic infiltration in the 9L gliosarcoma brain tumor model: implications for strategies of immunotherapy J Neuroimmunol 1992 36: 57–68
Oshiro S, Fukushima T, Tomonaga M, Black KL . Response of MHC class-1 antigen on rat glioma cells to cytokines Anticancer Res 2000 20: 605–610
Freeman SM et al. The ‘bystander effect’: tumor regression when a fraction of the tumor mass is genetically modified Cancer Res 1993 53: 5274–5283
Hamel W, Magnelli L, Chiarugi VP, Israel MA . Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells Cancer Res 1996 56: 2697–2702
Huang AY, Bruce AT, Pardoll DM, Levitsky HI . Does B7–1 expression confer antigen-presenting cell capacity to tumors in vivo? J Exp Med 1996 183: 769–776
Ramesh R et al. In vivo analysis of the ‘bystander effect’: a cytokine cascade Exp Hematol 1996 24: 829–838
Freeman SM et al. The role of cytokines in mediating the bystander effect using HSV-TK xenogeneic cells Cancer Lett 1995 92: 167–174
Matzinger P . Tolerance, danger, and the extended family Annu Rev Immunol 1994 12: 991–1045
Dranoff G et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte–macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity Proc Natl Acad Sci USA 1993 90: 3539–3543
Wakimoto H et al. Efficient retrovirus-mediated cytokine-gene transduction of primary-cultured human glioma cells for tumor vaccination therapy Jpn J Cancer Res 1997 88: 296–305
Chen L et al. Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer J Immunol 1997 159: 351–359
Lieu FH, Hawley TS, Fong AZ, Hawley RG . Transmissibility of murine stem cell virus-based retroviral vectors carrying both interleukin-12 cDNAs and a third gene: implications for immune gene therapy Cancer Gene Ther 1997 4: 167–175
Felzmann T, Ramsey WJ, Blaese M . Characterization of the antitumor immune response generated by treatment of murine tumors with recombinant adenoviruses expressing HSVtk, IL-2, IL-6 or B7–1 Gene Therapy 1997 4: 1322–1329
Benda P, Someda K, Messer J, Sweet WH . Morphological and immunochemical studies of rat glial tumors and clonal strains propagated in culture J Neurosurg 1971 34: 310–323
Barth RF . Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas J Neurooncol 1998 36: 91–102
Graham FL, Smiley J, Russell WC, Nairn R . Characteristics of a human cell line transformed by DNA from human adenovirus type 5 J Gen Virol 1977 36: 59–74
Moolten FL, Wells JM . Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors J Natl Cancer Inst 1990 82: 297–300
Ram Z et al. The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats J Neurosurg 1994 81: 256–260
Yei S et al. Adenovirus-mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung Gene Therapy 1994 1: 192–200
Graham FL, Prevec L . Adenovirus-based expression vectors and recombinant vaccines Biotechnology 1992 20: 363–390
Caruso M et al. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma Proc Natl Acad Sci USA 1996 93: 11302–11306
Barth RJJ, Bock SN, Mule JJ, Rosenberg SA . Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes J Immunol 1990 144: 1531–1537
Acknowledgements
We are grateful to Drs Natasha Caplen and John Morris for their critical review of the manuscript. We thank Drs Keiya Ozawa, Masafumi Onodera, and Junkoh Yamashita for their encouragement and support.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Okada, T., Shah, M., Higginbotham, J. et al. AV.TK-mediated killing of subcutaneous tumors in situ results in effective immunization against established secondary intracranial tumor deposits. Gene Ther 8, 1315–1322 (2001). https://doi.org/10.1038/sj.gt.3301526
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3301526
Keywords
This article is cited by
-
Adenovirus Expressing Both Thymidine Kinase and Soluble PD1 Enhances Antitumor Immunity by Strengthening CD8 T-cell Response
Molecular Therapy (2013)
-
Enhanced antitumoral efficacy and immune response following conditionally replicative adenovirus containing constitutive HSF1 delivery to rodent tumors
Journal of Translational Medicine (2012)
-
Neoadjuvant in situ gene-mediated cytotoxic immunotherapy improves postoperative outcomes in novel syngeneic esophageal carcinoma models
Cancer Gene Therapy (2011)
-
Anti-tumor immune responses following neoadjuvant immunotherapy with a recombinant adenovirus expressing HSP72 to rodent tumors
Cancer Immunology, Immunotherapy (2005)
-
Suicide gene therapy of sarcoma cell lines using recombinant adeno-associated virus 2 vectors
Cancer Gene Therapy (2004)